Descriptive Analysis of Retrospective Observational Real-World Evidence of a Monoclonal Anti-Amyloid Therapy Program in a Wide Catchment Specialty Memory Clinic.

introductionAnti-amyloid therapy (AAT) protocol complexity may widen specialty dementia care access gaps. The University of Colorado (CU) Advanced Therapy in Neurodegenerative Disorders (ATND) Clinic is within the CU-Memory Disorders Clinic (CU-MDC). The aim of this study is to report initial CU-ATND real-world evidence (RWE).

methodsPatients who completed CU-ATND Clinic intake paperwork were included (n = 123) and compared to CU-MDC (n = 1100) seen between April 2024 to June 2025. Demographic information was included for both clinics. Retrospective observational data on CU-ATND Clinic patients including work-up, decisions about pursing AAT, and adverse events at the time of data extraction was described.

resultsAAT status included patient declined (37.4%) or deferred (8.1%), clinically excluded (14.6%), undergoing work-up (8.1%), consented for infusions (26.0%), completed infusions (0.8%), and stopped infusions (4.1%). CU-ATND Clinic patients had a median age of 73 years and were 50.4% women with the majority white and urban-dwelling similar to the CU-MDC. AAT candidacy steps and decision duration varied. AAT-related adverse events were managed without extended inpatient admission or persistent effects.

conclusionMany care disparities were present prior to CU-ATND referral. The CU-ATND RWE highlights successes and provides insight into barriers impacting access.